Latest Breaking News On - Zhengbo song - Page 1 : comparemela.com

SUZHOU, China, June 14, 2022 /PRNewswire/ Alphamab Oncology (stock code: 9966.HK)announced thatthe first patient was dosed in a Phase I clinical study (KN052-CHN-001) of KN052, its proprietary PD-L1/OX40 bispecific antibody, in patients with advanced solid tumors in China. With the development of immunotherapy and further understanding of tumor pathogenesis, cancer therapy has entered a new era, among which PD-(L)1 inhibitors have become a star product. However, PD-1/PD-L1 inhibitors did not bring satisfiedresponse rate when used as monotherapy, and innovative treatment regimens are expected.KN052 is the world's first PD-L1/OX40 bispecific antibody entering first-in-human clinical study. It can effectively reverse tumor induced immune inhibition by blocking the PD-L1/PD-1 pathway and promote the immune response by activating OX40. In preclinical studies, KN052 showed significantly stronger activity than either single antibody or in combination. KN052-CHN-001 is a Phase I clinical

United statesHong kongHong kong stock exchangeEuropean unionChinese national medical products administrationNational medical products administrationZhengbo songZhejiang cancer hospitalJune 14022 prnewswire alphamab oncology stock code 9966 hk announced thatthe first patient was dosed ina phasei clinical study kn052 chn 001 ofTs proprietary pd l1 ox40 bispecific antibodyN patients with advanced solid tumors in china the development of immunotherapy and further understanding tumor pathogenesisAncer therapy has entereda new eraMong which pdl 1 inhibitors have becomea star product howeverD 1 pd l1 inhibitors did not bring satisfiedresponse rate when used as monotherapyNd innovative treatment regimens are expected kn052 is the world 39s first pd l1 ox40 bispecific antibody entering in human clinical study it can effectively reverse tumor induced immune inhibition by blocking 1 pathway and promote response activating preclinical studies